change at 180 minutes. Restlessness (n= 11) and increased pulse were seen 20 minBackground -Commercially available salbutamol is a racemic mixture consisting utes after racemic and R-salbutamol but not S-salbutamol or placebo, and not at of equal amounts of the two enantiomers, R-salbutamol and S-salbutamol, felt to be 180 minutes. There were no other adverse events. active and inert, respectively. Methods -A double blind, randomised, Conclusion -A single dose of 1.25 mg nebulised R-salbutamol produced equifour way, crossover study was performed in 12 well controlled asthmatic subjects valent bronchoprotection, bronchodilation, restlessness, and tachycardia as did (forced expiratory volume in one second (FEV 1 ) >70% predicted, no 2 agonists for 2.5 mg of racemic salbutamol. S-salbutamol 1.25 mg had a weak broncho-[4 weeks). Subjects were studied on four days at intervals of 48 hours to seven days. protective effect; this could be because of a small amount of contamination with R-FEV 1 was assessed before and both FEV 1 and methacholine PC 20 were measured 20 salbutamol or because S-salbutamol is an intrinsically weak 2 receptor stimulant. and 180 minutes after a single dose of nebulised racemic salbutamol 2.5 mg, (Thorax 1997;52:845-848 to 4.2) doubling doses, respectively, at 20 gested that the S enantiomer may be responsible for one or both of these effects, most
doubling doses at 20 minutes and no salbutamol, we undertook a double blind, four way, crossover study to compare single doses of nebulised S-salbutamol, R-salbutamol, recover spontaneously between the completion or respiratory tract infections for at least four weeks before and during the study. Inhaled of the first methacholine challenge and the measurement of spirometric parameters at 180 corticosteroids were permitted at a stable dose but were used by only one subject. The study minutes. A single dose of ipratropium bromide was occasionally administered following the was approved by the University of Saskatchewan ethics committee and written in-second methacholine challenge. Subjects refrained from the use of inhaled 2 agonists formed consent was obtained.
throughout the trial but had access to ipratropium bromide to use as needed for relief of symptoms; this was withheld for at least   Methacholine inhalation tests were carried out eight hours before all testing. by our standardised technique reported elsewhere. 6 7 Aerosols were generated with a Bennett twin jet nebuliser calibrated to deliver   
The primary end point was the log 10 methaan output of 0.13 ml/min. Aerosols were delivered to the patient via a loose-fitting face choline PC 20 for the four treatments at the two time periods. FEV 1 (% change from time 0 mask and inhaled by tidal breathing with the nose clipped. Subjects initially performed FEV 1 to both 20 and 180 minutes) was a secondary end point. These were analysed by a commanoeuvres in triplicate. Isotonic sterile saline, the diluent, was then inhaled for two minutes puterised ANOVA. Vital signs and restlessness (present or absent) were also compared at the and the FEV 1 repeated 30 and 90 seconds later. Following this, doubling concentrations of two times. methacholine from 0.03 to 64.0 mg/ml were inhaled for similar two minute tidal breathing periods at five minute intervals. The FEV 1 Results
All subjects completed the study without any was repeated 30 and 90 seconds after each inhalation and the percentage fall calculated significant adverse events. Changes in pulse rate and blood pressure are shown in table 2. from the lowest post-saline to the lowest postmethacholine FEV 1 . The study was continued There was a significant increase in the pulse rate from a mean (SE) value of 72.6 (2.8) to until there was an 18% or greater fall in FEV 1 and the PC 20 was extrapolated or interpolated 84.0 (3.2) beats/min (p<0.0001) 20 minutes after racemic salbutamol and from 71.3 (2.7) from the log dose-response curve as previously reported. 8 Starting concentrations for metha-to 84.1 (2.5) beats/min (p<0.0001) 20 minutes after R-salbutamol; there was no significant choline challenges were not always 0.3 mg/ml but, rather, were based on published guidelines 7 difference in the pulse rate at 180 minutes (p= 0.08). There was no change in blood pressure and our previous knowledge of the subject; however, for all methacholine challenges in a (table 2), respiratory rate, or temperature. Restlessness was reported by 11 subjects 20 minutes given individual the same starting concentration and dosage regimen were always after both R-salbutamol and racemic salbutamol but not after S-salbutamol (n=0) or used.
placebo (n=1) (table 2; p<0.01). The restlessness was frequently graded as severe; the average restlessness score at 20 minutes was   Subjects attended the laboratory on five 1.75 after R-salbutamol and 1.58 after racemic salbutamol compared with 0.17 after placebo occasions. On the first occasion spirometric parameters were measured and a baseline and 0 after S-salbutamol.
(95% CI 2.5 to 4.1) doubling doses above placebo (0.1 (0.14)), respectively. At 20 minutes after S-salbutamol the log 10 PC 20 was 0.36 (0.15) (0.9 (95% CI 0.3 to 1.5) doubling dose above placebo); this was significantly lower than log 10 PC 20 following racemic salbutamol and R-salbutamol and significantly larger than log PC 20 following placebo (p=0.0049). At 180 minutes there was still a significant treatment effect with log 10 PC 20 after R-salbutamol (0.59 (0.20)) and racemic salbutamol (0.52 (0.19)) which was significantly higher than following S-salbutamol (0.20 (0.19)) or placebo (0.23 (0.17)). These represent an increase of 1.2 (95% CI 0.6 to 1.8) and 1.0 (95% CI 0.2 at 180 minutes between log 10 PC 20 after S-salbutamol and after placebo. There was no treatment sequence effect (p >0.05).
Discussion
Nebulised racemic salbutamol (2.5 mg) and Rsalbutamol (1.25 mg) provided significant and similar bronchoprotection against methacholine at both 20 minutes and three hours compared with placebo and S-salbutamol (1.25 mg). The S-salbutamol provided slight bronchoprotection at 20 minutes but none at three hours. The study was not designed with bronchodilation as a major end point. However, there was significant bronchodilation at 20 minutes following racemic and R-salbutamol; at three hours the improved FEV 1 following racemic and R-salbutamol was significantly greater than the FEV 1 following S-salbutamol. Restlessness or shakiness and tachycardia were These data confirm that the R enantiomer is the active bronchodilating and bronchoprotecting molecule in humans. The R enantiomer also causes the tremor and The FEV 1 data are summarised in table 2 and fig 1. The baseline FEV 1 was similar on tachycardia. There was a weak, borderline, and short-lived bronchoprotecting effect of Sthe four days. There was a significant treatment effect (p=0.0001) on the FEV 1 at 20 min-salbutamol. At this point, considering that we used a large single dose of nebulised medutes, the mean percentage improvements after racemic salbutamol (12.4 (3.0)%) and R-sal-ication, the mechanism of action of S-salbutamol is not clear. It is possible that the small butamol (12.0 (3.1)%) being greater than after S-salbutamol or placebo. The improvement effect seen after this large single dose of Ssalbutamol could be either due to a weak inin FEV 1 of 5.2 (0.9)% 20 minutes after Ssalbutamol was not significantly different from trinsic effect on, or a low affinity for, the 2 receptor or due to the small (up to 1%) conplacebo (p=0.10). The FEV 1 at 180 minutes also showed a significant treatment effect (p= tamination with R-salbutamol.
Perrin-Fayolle recently reported a similar 0.021); pairwise comparisons showed a significant difference for % FEV 1 between S-study; 9 however, differences in study design make comparison with our data difficult. Forty salbutamol (−2.9 (2.1)%) and both racemic (5.7 (2.9)%) and R-salbutamol (5.2 (2.2)%), subjects completed a double blind parallel study with 10 subjects in each treatment arm but none was significantly different from placebo. The absolute values for mean (SE) and the doses used were smaller (an estimated 200 g racemic salbutamol and 100 g of the FEV 1 are shown in fig 1. There was no treatment sequence effect (p >0.05).
individual enantiomers). The results were analysed arithmetically rather than geometrically. There was a significant treatment effect on log methacholine PC 20 at both time periods (p A significant increase in methacholine PC 20 was seen 20 minutes after racemic salbutamol and <0.0001; fig 2) . At 20 minutes the log 10 PC 20 had increased from 0.03 (0.14) to 1.12 (0.16) R-salbutamol but not at 180 minutes. The PC 20 after S-salbutamol at 20 minutes was after racemic salbutamol and 1.10 (0.16) after R-salbutamol -3.4 (95% CI 2.6 to 4.2) and not significantly different from that following group.bmj.com on April 5, 2017 -Published by http://thorax.bmj.com/ Downloaded from placebo. However, at 180 minutes the PC 20 protection, our primary end point, but is not an ideal population in which to assess bronchoafter S-salbutamol was significantly lower than dilation. Hence, changes in FEV 1 were a secthe PC 20 after placebo, but apparently was not ondary end point. The study has <80% power significantly lower than baseline PC 20 in the S to detect a FEV 1 of <5% such as that seen 180 group. minutes after S-salbutamol. This also might not We believe the crossover design used in this be the ideal population in which to detect an study has advantages for several reasons. Preadverse effect of S-salbutamol. However, the vious studies in our laboratory have shown a data show that S-salbutamol had no adverse wide range of acute shift of methacholine PC 20 effects in these well controlled asthmatic subfollowing a single dose of racemic salbutamol jects and provide some reassurance prior to (or salmeterol). This inter-individual variability embarking upon multiple dose studies. can range from a low of about one to a high
In conclusion, we have shown that the R of more than five doubling dose improvement.
enantiomer of salbutamol causes the bronchoThere is also a concern regarding the per-dilation, bronchoprotection, restlessness, and formance of two methacholine tests within less tachycardia seen following racemic salbutamol. than three hours. There are two opposing pos-In our crossover study the large dose of Ssibilities. The first is that some subjects may salbutamol had a minor bronchoprotective demonstrate a tolerance to the effect of metha-effect at 20 minutes but was not significantly choline and show an increased PC 20 on the different from placebo at three hours. We are second test; this is known to occur in normal more concerned with the effect of regular dossubjects and very mild asthmatic patients both ing with racemic salbutamol and the possibility with regard to histamine and methacholine. 10 that regular dosing with S-salbutamol might By contrast, there is also the possibility of a have adverse effects, particularly on the airway cumulative effect of methacholine leading to response to allergen. These data provide a good the opposite result. This is also an area where background for commencing multiple dosing one might expect some inter-subject variability. studies. We feel that a crossover design offers the ad- 
